Trial Profile
A Study to Evaluate the Effectiveness and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Relapsed and Relapsed Refractory Multiple Myeloma: A real world experience
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association